PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

First European Framework Contracts for Influenza Pandemic Preparedness Awarded to Seqirus

Liverpool, UK – 8 April 2019

Seqirus, a global leader in influenza prevention, has announced that it has signed contracts with the European Commission and 15 European Union Member States to supply pandemic influenza vaccines as part of the response to a pandemic emergency. Seqirus is the first influenza vaccine manufacturer to sign pandemic contracts under the EU joint procurement framework.

A pandemic occurs when an influenza virus which was not previously circulating among humans and to which most people don’t have immunity emerges and transmits among humans. As the majority of the population has no immunity to these viruses, an outbreak can result in significant morbidity and mortality.1

The European Centre for Disease Prevention and Control estimates that a severe pandemic could infect up to a quarter of the population of the European Union, with many millions of cases and tens of thousands of deaths.2

“According to the WHO, influenza remains one of the world’s greatest public health challenges and the question is not whether we will have another pandemic, but when. We are committed to working with our partners to protect people around the world by providing rapid access to influenza vaccines during a pandemic emergency,” said Gordon Naylor, President, Seqirus.

With leading influenza vaccine technologies and expertise dating back to the Spanish flu pandemic of 1918, Seqirus is a trusted partner to governments around the world.

The development of the EU joint procurement framework was driven by the H1N1 influenza pandemic in 2009, which highlighted the lack of consistency in access to pandemic vaccines between EU countries.

The WHO’s Global Influenza Strategy for 2019 – 2030 states that a severe pandemic can result in widespread social and economic effects, including a loss of national economic productivity and severe economic burdens on affected citizens and communities. 3

Seqirus is committed to working with key stakeholders in public health to develop a range of effective pandemic preparedness solutions, including stockpiling vaccines for first responders to help protect communities and mitigate the potentially devastating economic and social impact of an influenza pandemic.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026